Open AccessSynthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells.
Author(s) -
Babette B. Weksler,
Aaron J. Marcus,
Eric Jaffe
Publication year - 1977
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.74.9.3922
Subject(s) - prostacyclin , prostaglandin , tranylcypromine , endothelial stem cell , chemistry , prostaglandin e2 , prostaglandin antagonist , prostaglandin e , biochemistry , pharmacology , endocrinology , medicine , biology , in vitro , enzyme , monoamine oxidase
Cultured endothelial cells derived from human umbilical veins or bovine aorta produce a potent inhibitor of platelet aggregation. The inhibitor is synthesized from sodium arachidonate or or prostaglandin endoperoxides by a microsomal enzyme system. Tranylcypromine, a specific antagonist of prostacyclin synthetase, suppresses production of the inhibitor by endothelial cells. The inhibitor, which is ether extractable, has been identified using a two-step thin-layer radiochromatographic procedure and a synthetic prostaglandin I2 standard.With this procedure, we have shown that human and bovine endothelial cells convert sodium [3H]arachidonate to radiolabeled prostaglandin I2 and 6-keto-prostaglandin F1alpha, as wellas prostaglandin E2. Thus, endothelial cells may be non-thrombogenic in vivo because they synthesize and release prostaglandin I2, a potent inhibitor of platelet aggregation.